Acrivon Therapeutics (ACRV) Free Cash Flow (2021 - 2026)
Acrivon Therapeutics (ACRV) posted quarterly Free Cash Flow of -$20.6 million for Q1 2026, down 4.89% year-over-year from -$21.6 million in Q1 2025, and down 32.97% quarter-over-quarter from -$15.5 million in Q4 2025.
Acrivon Therapeutics (ACRV) Free Cash Flow (2021 - 2026) Analysis & Trends
Acrivon Therapeutics (ACRV) has reported Free Cash Flow for 6 consecutive years, with -$20.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Free Cash Flow fell 4.89% year-over-year to -$20.6 million; the TTM figure through Mar 2026 stood at -$66.3 million (up 3.28% YoY), while the FY2025 annual figure was -$65.3 million, up 2.26% from the prior year.
- Free Cash Flow declined to -$20.6 million in Q1 2026 per ACRV's latest filing, from -$15.5 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$6.9 million in Q2 2022 and bottomed at -$20.6 million in Q1 2026.
- Historically, Free Cash Flow has averaged -$13.5 million across 5 years, with a median of -$13.5 million in 2023.
- Annual changes were most pronounced in 2022 — Free Cash Flow sank 155.18% — and 2025, when it rose 24.89%.
- Acrivon Therapeutics' Free Cash Flow stood at -$9.6 million in 2022, then slumped by 40.73% to -$13.5 million in 2023, then declined by 28.43% to -$17.4 million in 2024, then climbed by 10.97% to -$15.5 million in 2025, then sank by 32.97% to -$20.6 million in 2026.
- Business Quant data shows ACRV's Free Cash Flow at -$20.6 million in Q1 2026, -$15.5 million in Q4 2025, and -$13.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Acrivon Therapeutics | 92.89 Mn | 92.89 Mn | - | -14.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -14.95 Mn |
| Jun 30, 2026 | -14.95 Mn |
| Mar 31, 2026 | -20.55 Mn |
| Mar 31, 2026 | -20.55 Mn |
| Dec 31, 2025 | -15.46 Mn |
| Dec 31, 2025 | -15.46 Mn |
| Sep 30, 2025 | -13.18 Mn |
| Sep 30, 2025 | -13.18 Mn |
| Jun 30, 2025 | -17.10 Mn |
| Jun 30, 2025 | -17.10 Mn |
| Mar 31, 2025 | -19.59 Mn |
| Mar 31, 2025 | -19.59 Mn |
| Dec 31, 2024 | -17.36 Mn |
| Dec 31, 2024 | -17.36 Mn |
| Sep 30, 2024 | -17.55 Mn |
| Sep 30, 2024 | -17.55 Mn |
| Jun 30, 2024 | -14.04 Mn |
| Jun 30, 2024 | -14.04 Mn |
| Mar 31, 2024 | -17.90 Mn |
| Mar 31, 2024 | -17.90 Mn |